NCL ICB has commissioned a programme of work from January 2025 to March 2026, to review patients with CKD stages G3a-G5 who could be prescribed an SGLT2 inhibitor, but who are not currently prescribed the medication. This intervention will be beneficial to the patient’s health and self-management of their condition. 

SGLT-2i used appropriately in CKD can impact significantly on both the rates of heart attacks and strokes in these patients, but also to reduce the number who reach end stage kidney disease and renal replacement therapy. 

To support this work, clinicians with a prescribing role are invited to join a one hour interactive session with experts from the NCL CKD Integrated Service.

Please note: you will need Q&A access, and to respond to polls. To do this, you need to:1.    Join the meeting from the MS Teams app and not through the browser2.    Have access to click on links or scan a QR code.

You will learn

• what the benefits are to prescribing an SGLT-2 inhibitor in CKD when appropriate, for both patients and the wider healthcare system
• how suitable patients have been identified through searches? Who should we focus on
• what the updated NCL CKD Pathway (launched January 2025) recommendations are for using SGLT-2i in CKD.

All sessions are 1-2pm

• Register for Wednesday 12 February 
• Register for Thursday 27 February
• Register for Friday 7 March
• Register for Tuesday 11 March
• Register for Tuesday 1 April  
• Register for Wednesday 2 April
• Register for Friday 25 April
• Register for Tuesday 13 May
• Register for Tuesday 3 June
• Register for Monday 9 June
• Register for Thursday 26 June
• Register for Wednesday 2 July
• Register for Tuesday 8 July

Event dates will be released throughout the year, until February 2026, with meeting links provided within two months of the event.

Booking is by registration only, and live attendance is required for certification.